Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing
BACKGROUND: The high worldwide genetic diversity of HIV poses significant challenges for its detection and diagnosis by nucleic acid testing (NAT). Well-characterized reference panels are important for evaluating the analytical performance of HIV tests. OBJECTIVE: To develop a reference panel for HIV NAT that reflects the genetic diversity of circulating strains. STUDY DESIGN: HIV was cultured from blood specimens collected from blood donor and clinical sites in Cameroon. Metagenomic next-generation sequencing in combination with spiked primer enrichment along with Sanger sequencing were used to sequence 101 cultured HIV-1 samples representing 59 strains. To establish an HIV-1 variant reference panel, a diverse subset of cultured viruses was analyzed in multiple laboratories with different assays to determine consensus viral loads. RESULTS: Near full-length HIV-1 genomes, with an average of 9589 base pairs (bp), were recovered from 37 (62.7%) of the 59 strains. The whole genome sequences of 28 strains exhibited more than 95% similarity to our previously reported genomes obtained by Sanger sequencing. An HIV variant reference panel for NAT comprising 18 diverse HIV-1 strains was developed. The panel included four subtypes, four circulating recombinant forms, and eight unique recombinant forms. Strains were prepared at low (n = 18, 2.53 log10 copies/mL), medium (n = 18, 3.61 log10 copies/mL), and high viral loads (n = 15, 4.66 log10 copies/mL), yielding 51 panel members in total. CONCLUSION: This diverse HIV reference panel can be used to evaluate the performance of HIV NAT and is available upon request to developers and manufacturers of HIV tests.
Authors
- Viswanath Ragupathy (ORCID: https://orcid.org/0000-0003-2509-2805)
- Jessica A. DeQuach
- Hanxia Huang (ORCID: https://orcid.org/0000-0002-1753-7053)
- Alicia Sotomayor-González (ORCID: https://orcid.org/0000-0002-8930-745X)
- Santanu Biswas (ORCID: https://orcid.org/0000-0003-4056-4305)
- Charles Y. Chiu (ORCID: https://orcid.org/0000-0003-2915-2094)
- David R. McGivern (ORCID: https://orcid.org/0000-0003-3497-5087)
- Jiangqin Zhao (ORCID: https://orcid.org/0000-0003-4672-0735)
- Cassie Porth
- Melissa Hunsicker
- Tianxiong Li
- Indira Hewlett (ORCID: https://orcid.org/0000-0002-2951-7885)
- Venice Servellita (ORCID: https://orcid.org/0000-0002-1745-4012)
- Oksana Yakovleva
- Helene Highbarger
- Jose D. Morales
- Ethan Sun
- Patricia Barilko
- Samantha Huynh
- Thomas N. Denny
- Robin L. Dewar
- Xue Wang
Institutions
- Naval Medical Research Command (US)
- United States Food and Drug Administration (US)
- Duke University (US)
- University of California, San Francisco (US)
- Integrated Dynamic Electron Solutions (United States) (US)
- Hologic (United States) (US)
- Frederick National Laboratory for Cancer Research (US)
- Science Applications International Corporation (United States) (US)
Publication Details
- Journal
- Journal of Clinical Virology
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1016/j.jcv.2026.105941
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- U.S. Food and Drug Administration
- University of California, San Francisco
- Center of Excellence in Regulatory Science and Innovation
- National Heart, Lung, and Blood Institute
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases